Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27533876 | 0.84 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL30089542 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL28053559 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL15979732 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL166468 | 0.80 | PTPN1 (0.57) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL29758522 | 0.80 | PTPN1 (0.57) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL3703924 | 0.80 | ALDH1A1 (0.51) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL8740774 | 0.80 | PTPN1 (0.57) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL634331 | 0.78 | KMT2A (0.53) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL12430466 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398151-B2 | Sumo inhibitor compounds and uses thereof | Suvalent Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | disclosed |
| US-11254687-B2 | Organic light-emitting material and manufacturing method thereof, and organic light-emitting device | WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2022-02-22 | — | — | US | disclosed |
| US-20210403481-A1 | ORGANIC LIGHT-EMITTING MATERIAL AND MANUFACTURING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DEVICE | WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| CN-108947900-A | The method of carbon arylation tandem reaction synthesizing heterocyclic compound of the photoinduction without metal catalytic | 河南大学 | 2018-12-07 | — | — | CN | disclosed |
| CN-1458922-A | Urea derivative and adhesive-molecule inhibitor containing same as ctive ingredient | TORAY INDUSTRIES (JP) | 2003-11-26 | — | — | CN | disclosed |
| EP-0653421-B1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5552557-A | Process for preparing 2-cyanoimidazole compounds by reaction of an amino ketone compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1996-09-03 | — | — | US | disclosed |
| EP-0653421-A1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254687-B2 | Organic light-emitting material and manufacturing method thereof, and organic light-emitting device | CYBA, SLC43A1, ABCB1 | ALDH1A1 372/4885HPGD 1594/4885SMN1; SMN2 3287/4885 |
| US-12398151-B2 | Sumo inhibitor compounds and uses thereof | SUMO1, SUMO2, SUMO3 | ALDH1A1 1950/4885HPGD 2822/4885SMN1; SMN2 4083/4885 |
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | ALDH1A1 1950/4885HPGD 2822/4885SMN1; SMN2 4083/4885 |
| US-20210403481-A1 | ORGANIC LIGHT-EMITTING MATERIAL AND MANUFACTURING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DEVICE | CYBA, SLC43A1, ABCB1 | ALDH1A1 372/4885HPGD 1594/4885SMN1; SMN2 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.